<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599507</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-047</org_study_id>
    <nct_id>NCT01599507</nct_id>
  </id_info>
  <brief_title>Study of FG-4592 in Subjects With Chronic Kidney Disease in China</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose Ranging Safety and Efficacy Study of FG 4592 in Non-dialysis Chronic Kidney Disease (CKD) Subjects With Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate efficacy and safety of FG-4592 in the
      correction of anemia in non-dialysis chronic kidney disease patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose ranging study with two consecutive dose escalation cohorts. The study objective is to
      demonstrate that FG-4592 is effective in the correction of anemia in chronic kidney disease
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change in hemoglobin by Week 9 from baseline</measure>
    <time_frame>Week 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a target Hb level ≥11 g/dL by Weeks 5,6,7,8 and 9.</measure>
    <time_frame>Week 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a Hb increase from baseline ≥1.0 g/dL.</measure>
    <time_frame>Week 9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Anemia in Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>FG-4592</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>TIW dosing, capsule</description>
    <arm_group_label>FG-4592</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TIW dosing, capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 75 years

          2. Subject has voluntarily signed and dated an informed consent form

          3. Chronic Kidney Disease, not receiving dialysis

          4. Hemoglobin (Hb) values in 4 screening visits and the mean Hb must be &lt;10g/dL

          5. Aminotransferase levels (alanine aminotransferase [ALT], aspartate aminotransferase
             [AST]) and total bilirubin must be ≤ upper limit of normal (ULN) during the screening
             period

          6. Serum alkaline phosphatase (ALP) ≤2x ULN during screening period. Subjects with serum
             ALP values between 1 x and 2 x ULN may be included only if bone-specific ALP (BSAP) is
             also elevated &gt; ULN

          7. Total bilirubin values must be ≤ULN during screening period

          8. Serum folate and vitamin B12 levels above the lower limit of normal (LLN)

          9. Body weight: 40 to 100 kg (dry weight) inclusive

         10. Body mass index (BMI): 16 to 38 kg/m2 inclusive

        Exclusion Criteria:

          1. Received any erythropoiesis-stimulating agent (ESA) other than epoetin alfa within 12
             weeks prior to Day 1

          2. Any clinically significant infection or evidence of an underlying infection such as a
             white blood cell count (WBC) &gt; ULN during screening on two separate occasions,

          3. Positive for any of the following: human immunodeficiency virus (HIV); hepatitis B
             surface antigen (HBsAg); anti-hepatitis C virus antibody (anti-HCV Ab)

          4. History of chronic liver disease

          5. New York Heart Association Class III or IV congestive heart failure

          6. Chronic inflammatory disease other than glomerulonephritis that could impact
             erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac
             disease) even if it is currently in remission

          7. Active or chronic gastrointestinal bleeding, or a known coagulation disorder

          8. Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all types,
             etc.)

          9. Hematological disorders, including myelodysplastic syndrome, multiple myeloma, or pure
             red cell aplasia

         10. History of hemosiderosis, hemochromatosis, polycystic kidney disease, or anephric

         11. Active hemolysis or diagnosis of hemolytic syndrome

         12. Known bone marrow fibrosis

         13. Uncontrolled or symptomatic secondary hyperparathyroidism (PTH&gt;600ng/L)

         14. Any prior organ transplantation

         15. Drug-treated gastroparesis, short-bowel syndrome, or any other gastrointestinal
             condition that may lead to reduced absorption of study drug

         16. Serum albumin &lt;3 g/dL

         17. History of alcohol or drug abuse; or a positive drug screen for a substance that has
             not been prescribed for the subject

         18. Prior treatment with FG-4592

         19. Use of an investigational medication or treatment, or carryover effect of an
             investigational treatment expected, during the screening visit, treatment and
             follow-up period.

         20. Use of traditional Chinese medicines (TCM) during the screening visit to Day 1 or
             plans to use TCM during the study unless approved in advance by the Medical Monitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First affiliated hospital of Dalian medical university</name>
      <address>
        <city>DaLian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang University No 1. Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Zheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XinHua Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Renal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

